Herpes simplex virus-1 (HSV-1) infection induces a potent but ineffective IFN-λ production in immune cells of AD and PD patients.
Aged
Aged, 80 and over
Alzheimer Disease
/ blood
Female
Gene Expression Regulation, Viral
Herpes Simplex
/ complications
Herpesvirus 1, Human
/ genetics
Humans
Interferons
/ biosynthesis
Interleukin-10
/ biosynthesis
Interleukin-1beta
/ biosynthesis
Male
Parkinson Disease
/ blood
RNA, Messenger
/ genetics
Viral Load
/ genetics
Alzheimer’s disease
HSV-1
IFN-λ
Immune response
Parkinson’s disease
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 08 2019
27 08 2019
Historique:
received:
03
06
2019
accepted:
18
08
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
17
7
2020
Statut:
epublish
Résumé
The sequential activation of immediate early (IE), early (E) and late (L) genes is required to allow productive herpes simplex virus type 1 (HSV-1) infection. Several evidences suggest that, together with inflammation, an immunological response incapable to counteract HSV-1 reactivation plays a role in the pathogenesis of Alzheimer's (AD) and Parkinson's (PD) diseases. IFN-lambda (IFN-λ), a cytokine endowed with a robust antiviral activity, contains HSV-1 reactivation. HSV-1-induced IFN-λ, IL-10 and IL-1β as well as the expression of viral IE, E and L genes were analyzed in vitro in peripheral blood mononuclear cells (PBMC) of AD and PD patients as well as of healthy controls (HC). PBMC of AD, PD and HC were in vitro infected with one multiplicity of infection (1 MOI) HSV-1. IE, E, and L viral genes transcription as well as IFN-λ, IL-10 and IL-1β production were analyzed. In HSV-1-infected cells of AD and PD patients compared to HC: (1) transcription of IE (ICP0, ICP27) genes was reduced whereas that of E (UL41, UL29) and L (UL48, LAT) genes was increased; (2) IFN-λ mRNA expression was increased. IL-1β was augmented and IL-10 was reduced in unstimulated cells of AD and PD compared to HC; HSV-1 infection significantly increased IL-10 production in HC alone. Data herein show that a proinflammatory condition is present in AD and PD, in whom attempts to obstacle viral replication via an initial, possibly more potent IFN-λ-mediated control of IE viral genes is unsuccessful.
Sections du résumé
BACKGROUND
The sequential activation of immediate early (IE), early (E) and late (L) genes is required to allow productive herpes simplex virus type 1 (HSV-1) infection. Several evidences suggest that, together with inflammation, an immunological response incapable to counteract HSV-1 reactivation plays a role in the pathogenesis of Alzheimer's (AD) and Parkinson's (PD) diseases. IFN-lambda (IFN-λ), a cytokine endowed with a robust antiviral activity, contains HSV-1 reactivation. HSV-1-induced IFN-λ, IL-10 and IL-1β as well as the expression of viral IE, E and L genes were analyzed in vitro in peripheral blood mononuclear cells (PBMC) of AD and PD patients as well as of healthy controls (HC).
METHODS
PBMC of AD, PD and HC were in vitro infected with one multiplicity of infection (1 MOI) HSV-1. IE, E, and L viral genes transcription as well as IFN-λ, IL-10 and IL-1β production were analyzed.
RESULTS
In HSV-1-infected cells of AD and PD patients compared to HC: (1) transcription of IE (ICP0, ICP27) genes was reduced whereas that of E (UL41, UL29) and L (UL48, LAT) genes was increased; (2) IFN-λ mRNA expression was increased. IL-1β was augmented and IL-10 was reduced in unstimulated cells of AD and PD compared to HC; HSV-1 infection significantly increased IL-10 production in HC alone.
CONCLUSIONS
Data herein show that a proinflammatory condition is present in AD and PD, in whom attempts to obstacle viral replication via an initial, possibly more potent IFN-λ-mediated control of IE viral genes is unsuccessful.
Identifiants
pubmed: 31455413
doi: 10.1186/s12967-019-2034-9
pii: 10.1186/s12967-019-2034-9
pmc: PMC6712644
doi:
Substances chimiques
Interleukin-1beta
0
RNA, Messenger
0
interferon-lambda, human
0
Interleukin-10
130068-27-8
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
286Références
Jpn J Infect Dis. 1999 Jun;52(3):89-98
pubmed: 10507986
J Virol. 2000 Aug;74(16):7196-203
pubmed: 10906173
J Virol. 2000 Dec;74(24):11464-71
pubmed: 11090142
J Invest Dermatol. 2001 Jan;116(1):150-6
pubmed: 11168811
J Leukoc Biol. 2001 Jan;69(1):149-57
pubmed: 11200059
Annu Rev Genomics Hum Genet. 2000;1:507-37
pubmed: 11701639
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Clin Microbiol Rev. 2003 Jan;16(1):96-113
pubmed: 12525427
J Neurovirol. 2003 Apr;9(2):194-204
pubmed: 12707850
J Clin Invest. 1992 Jun;89(6):1849-56
pubmed: 1318324
J Immunol. 1992 Jul 1;149(1):181-7
pubmed: 1318897
Nat Med. 2004 Jul;10 Suppl:S10-7
pubmed: 15272267
J Med Virol. 2005 Feb;75(2):300-6
pubmed: 15602731
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):241-7
pubmed: 15623779
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
Rev Med Virol. 2007 May-Jun;17(3):205-15
pubmed: 17295428
Neurosci Lett. 2007 Dec 18;429(2-3):95-100
pubmed: 17980964
Cell Mol Life Sci. 2008 Jun;65(11):1653-68
pubmed: 18351291
Biochim Biophys Acta. 2009 Jul;1792(7):714-21
pubmed: 18760350
J Pathol. 2009 Jan;217(1):131-8
pubmed: 18973185
Virol J. 2009 May 13;6:56
pubmed: 19439086
Lipids Health Dis. 2010 Jan 28;9:8
pubmed: 20109174
Sex Transm Infect. 2010 Jun;86(3):202-6
pubmed: 20410080
J Interferon Cytokine Res. 2010 Aug;30(8):555-64
pubmed: 20712453
PLoS One. 2010 Nov 15;5(11):e13989
pubmed: 21085580
PLoS One. 2011 Mar 31;6(3):e17966
pubmed: 21483850
Neurobiol Aging. 2012 Mar;33(3):624.e11-22
pubmed: 21514692
Sci Transl Med. 2011 Jun 29;3(89):89ra57
pubmed: 21715678
Expert Rev Mol Med. 2011 Sep 20;13:e30
pubmed: 21933454
J Neurosci Res. 2012 Feb;90(2):399-406
pubmed: 22057682
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18820-4
pubmed: 22065742
J Neurosci Res. 2012 May;90(5):1020-9
pubmed: 22252837
Biol Blood Marrow Transplant. 2013 Apr;19(4):529-37
pubmed: 23313704
Nat Commun. 2013;4:1983
pubmed: 23770917
Crit Rev Toxicol. 2013 Jul;43(6):515-34
pubmed: 23844699
Dis Markers. 2013;35(3):181-5
pubmed: 24167364
J Allergy Clin Immunol. 2014 Jul;134(1):127-34
pubmed: 24655576
PLoS Pathog. 2014 Jul 24;10(7):e1004237
pubmed: 25058429
Mol Neurodegener. 2014 Aug 25;9:31
pubmed: 25152012
Front Aging Neurosci. 2014 Oct 15;6:285
pubmed: 25360113
Virology. 2015 May;479-480:562-7
pubmed: 25771487
J Neuroimmunol. 2015 Jun 15;283:50-7
pubmed: 26004156
J Neuroimmunol. 2016 Feb 15;291:110-4
pubmed: 26857504
J Parkinsons Dis. 2016;6(1):119-24
pubmed: 26889634
Mol Neurodegener. 2016 Mar 03;11:23
pubmed: 26939933
Virol J. 2016 Mar 08;13:38
pubmed: 26952111
J Alzheimers Dis. 2016 Oct 18;54(4):1273-1281
pubmed: 27497484
Cytokine. 2016 Dec;88:251-258
pubmed: 27697702
Expert Rev Anti Infect Ther. 2017 Feb;15(2):89-91
pubmed: 27882822
J Zhejiang Univ Sci B. 2017 Apr.;18(4):277-288
pubmed: 28378566
J Immunol Res. 2017;2017:7261980
pubmed: 28491875
FASEB J. 2017 Aug;31(8):3216-3226
pubmed: 28765170
J Neuroimmunol. 2017 Sep 15;310:26-31
pubmed: 28778441
J Alzheimers Dis. 2017;60(3):1055-1063
pubmed: 28984602
Front Aging Neurosci. 2018 Mar 06;10:48
pubmed: 29559905
Int J Alzheimers Dis. 2018 Jun 21;2018:1672568
pubmed: 30034864
J Intern Med. 2018 Dec;284(6):643-663
pubmed: 30051512
Front Neurol. 2019 Feb 19;10:122
pubmed: 30837941
Acta Neuropathol. 2019 Apr 20;:null
pubmed: 31006067
Eur Neurol. 1977;15(1):25-33
pubmed: 323017
J Virol. 1972 Jan;9(1):143-59
pubmed: 4110104
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Mech Ageing Dev. 1984 Nov;28(1):47-55
pubmed: 6513613
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
Lancet. 1997 Jan 25;349(9047):241-4
pubmed: 9014911
J Leukoc Biol. 1998 Apr;63(4):486-92
pubmed: 9544579
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759